Publications by authors named "Sundar Jagannath"

100Publications

Selinexor, bortezomib, and dexamethasone (SVD) in heavily treated relapsed refractory multiple myeloma.

Ann Hematol 2020 Oct 2. Epub 2020 Oct 2.

Department of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, 10 East 102nd Street, 6th Floor, New York, NY, 10029, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-020-04293-yDOI Listing
October 2020

Immunomodulatory drug- and proteasome inhibitor-backbone regimens in the treatment of relapsed multiple myeloma: an evidence-based review.

Expert Rev Hematol 2020 Sep 30;13(9):943-958. Epub 2020 Aug 30.

Multiple Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai , New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2020.1804356DOI Listing
September 2020

Timing of Autologous Stem Cell Transplantation for Multiple Myeloma in the Era of Current Therapies.

Clin Lymphoma Myeloma Leuk 2020 Oct 7;20(10):e734-e751. Epub 2020 Jun 7.

Department of Medicine, Icahn School of Medicine at Mount Sinai, York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2020.05.027DOI Listing
October 2020

Where you live can impact your cancer risk: a look at multiple myeloma in New York City.

Ann Epidemiol 2020 08 15;48:43-50.e4. Epub 2020 May 15.

Department of Population Health Science and Policy, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY; Division of General Internal Medicine, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.annepidem.2020.05.005DOI Listing
August 2020

Myeloma CAR-T CRS Management With IL-1R Antagonist Anakinra.

Clin Lymphoma Myeloma Leuk 2020 Sep 11;20(9):632-636.e1. Epub 2020 May 11.

Department of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2020.04.020DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7484011PMC
September 2020

Selinexor: a first-in-class SINE compound for treatment of relapsed refractory multiple myeloma.

Future Oncol 2020 Jul 8;16(19):1331-1350. Epub 2020 Jun 8.

Icahn School of Medicine at Mount Sinai Tisch Cancer Institute, New York 10029, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2020-0054DOI Listing
July 2020

Increased Muscle CXCR4 Expression in the Setting of Rare Muscle-invasive Multiple Myeloma.

Clin Lymphoma Myeloma Leuk 2020 06 7;20(6):e341-e344. Epub 2020 Mar 7.

Department of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2020.02.016DOI Listing
June 2020

Consensus Recommendations for the Clinical Management of Patients With Multiple Myeloma Treated With Selinexor.

Clin Lymphoma Myeloma Leuk 2020 06 7;20(6):351-357. Epub 2020 Mar 7.

Division of Hematology and Oncology, Department of Medicine, Columbia University, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2019.12.026DOI Listing
June 2020

Selinexor for the treatment of multiple myeloma.

Expert Opin Pharmacother 2020 Mar 19;21(4):399-408. Epub 2020 Jan 19.

Karyopharm Therapeutics, Newton, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2019.1707184DOI Listing
March 2020

Selinexor for Refractory Multiple Myeloma. Reply.

N Engl J Med 2019 11;381(20):1977-1978

Mount Sinai Hospital, New York, NY

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1912625DOI Listing
November 2019

Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.

N Engl J Med 2019 08;381(8):727-738

From the Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai (A.C., S.P., S.J.), and New York University Langone Medical Center (D.K.) - both in New York; the Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia (D.T.V.); the School of Medicine, National and Kapodistrian University of Athens, Athens (M.G., M. Dimopoulos); the Winship Cancer Institute, Emory University, Atlanta (A.K.N., S.L.); Massachusetts General Hospital Cancer Center (A.J.Y.), Tufts Medical Center (R.L.C.), and the Dana-Farber Cancer Institute (P.G.R.), Boston, and Karyopharm Therapeutics, Newton (M.G.K., S.S., L.L., S. Tang, C.P., J.-R.S.-M., M.C., H.C., Y.L., J.S.) - all in Massachusetts; Johns Hopkins University, Baltimore (C.A.H.); the University of Nantes, Nantes (P.M.), Hôpital Necker (L.F.), Hôpital Saint-Antoine (M.M.), and La Pitié-Salpêtrière Hospital (S.C.), Paris, University Hospital, Lille (T.F.), Centre Hospitalier Lyon Sud, Pierre-Benite (L.K.), and Centre Hospitalo-Universitaire Vandoeuvre-lès-Nancy, Nancy (A.P.) - all in France; the Mayo Clinic, Rochester, MN (D.D.); the University of Michigan, Ann Arbor (C.C.); the Mayo Clinic of Arizona, Phoenix (A.K.S.); Hackensack University Medical Center, Hackensack, NJ (J.R.); Washington University School of Medicine, St. Louis (R.V.); Lineberger Comprehensive Cancer Center at University of North Carolina-Chapel Hill, Chapel Hill (S. Tuchman); the University of Heidelberg, Heidelberg (M.S.R.), University Medical Center Hamburg-Eppendorf, Hamburg (K.C.W.), the University of Tübingen, Tübingen (K.C.W.), University Hospital Würzburg, Würzburg (M.S.), the University of Freiburg, Freiburg (M.E.), and Gemeinschaftspraxis Hämatologie-Onkologie, Dresden (T.I.) - all in Germany; the University of Leuven, Leuven (M. Delforge), Institut Jules Bordet, Université Libre de Bruxelles, Brussels (N.M.), University Hospital Ghent, Ghent (P.V.), and Centre Hospitalier Universitaire Université Catholique de Louvain Namur, Yvoir (C.D.) - all in Belgium; Vanderbilt University Medical Center, Nashville (R.F.C.); Sylvester Cancer Center, University of Miami, Miami (J.E.H.); the University of Alabama at Birmingham, Birmingham (L.J.C.); Yale School of Medicine, New Haven, CT (T.L.P.); Baylor University Medical Center, Dallas (M.L.); the David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles (G.S.); and University Hospital Krems, Karl Landsteiner University of Health Sciences, Krems an der Donau, Austria (K.P.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1903455
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1903455DOI Listing
August 2019

SOHO State of the Art Updates and Next Questions: T-Cell-Directed Immune Therapies for Multiple Myeloma: Chimeric Antigen Receptor-Modified T Cells and Bispecific T-Cell-Engaging Agents.

Clin Lymphoma Myeloma Leuk 2019 09 7;19(9):537-544. Epub 2019 Aug 7.

Tisch Cancer Institute, Icahn School of Medicine at Mt Sinai, New York, NY. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S21522650193125
Publisher Site
http://dx.doi.org/10.1016/j.clml.2019.08.002DOI Listing
September 2019

Monoclonal Gammopathy May Be of Unpredictable Significance.

JAMA Oncol 2019 Jul 18. Epub 2019 Jul 18.

Genomics of Myeloma Laboratory, L'Institut Universitaire du Cancer Oncopole, Toulouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2019.1580DOI Listing
July 2019

Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma.

N Engl J Med 2019 05;380(18):1726-1737

From the Massachusetts General Hospital Cancer Center (N.R., M.V.M.), Beth Israel Deaconess Medical Center (J.R.), and Dana-Farber Cancer Institute and Veterans Affairs Boston Healthcare System (N.M.), Boston, and Bluebird Bio, Cambridge (A.T., L.-P.L., R.A.M., K.F., M.M., F.P., M.T.Q.) - all in Massachusetts; Sarah Cannon Research Institute and Tennessee Oncology, Nashville (J.B.); Mayo Clinic, Rochester, MN (Y.L.); Hackensack University Medical Center, Hackensack (D.S.), and Celgene, Summit (J.W., G.R., Z.Y.) - both in New Jersey; Mount Sinai Medical Center, New York (S.J., D.M.); Stanford University Medical Center, Palo Alto (M.L.), and Celgene, San Francisco (T.C., K.H.) - both in California; and the Experimental Transplantation and Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD (J.N.K.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1817226
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1817226DOI Listing
May 2019

Are 4-Drug Regimens Here to Stay? Role in Induction and Salvage Therapies.

Cancer J 2019 Jan/Feb;25(1):32-37

From the Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PPO.0000000000000351DOI Listing
March 2020

Society of Hematologic Oncology State of the Art Update and Next Questions: Multiple Myeloma.

Clin Lymphoma Myeloma Leuk 2018 11 20;18(11):693-702. Epub 2018 Sep 20.

Division of Hematology and Medical Oncology, Tisch Cancer Institute, Mount Sinai Medical Center, New York, NY.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S21522650183135
Publisher Site
http://dx.doi.org/10.1016/j.clml.2018.09.003DOI Listing
November 2018

Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study.

Br J Haematol 2018 08 29;182(4):495-503. Epub 2018 May 29.

Harvard Medical School, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15384DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6105456PMC
August 2018

Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma.

J Clin Oncol 2018 03 30;36(9):859-866. Epub 2018 Jan 30.

Dan T. Vogl, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; David Dingli, Mayo Clinic, Rochester, MN; Robert Frank Cornell, Vanderbilt University Medical Center, Nashville, TN; Carol Ann Huff, Johns Hopkins University, Baltimore, MD; Sundar Jagannath, Tisch Cancer Institute, Mount Sinai School of Medicine; David Kaminetzky, New York University Langone Medical Center; Ajai Chari, Icahn School of Medicine at Mount Sanai, New York, NY; Divaya Bhutani and Jeffrey Zonder, Karmanos Cancer Institute, Wayne State University, Detroit; Craig Cole, University of Michigan, Ann Arbor, MI; Rachid Baz, H. Lee Moffitt Cancer Center and Research Institute, Tampa; James E. Hoffman, Sylvester Cancer Center, University of Miami, Miami, FL; Ajay Nooka, Winship Cancer Institute, Emory University, Atlanta, GA; Joshua Richter and David Siegel, John Theurer Cancer Center at the Hackensack University Medical Center, Hackensack, NJ; Ravi Vij, Washington University School of Medicine, St Louis, MO; Andrzej Jakubowiak, University of Chicago Medical Center, Chicago, IL; Rafat Abonour, Indiana University Cancer Center, Indianapolis, IN; Gary Schiller, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA; Terri L. Parker, Yale School of Medicine, New Haven, CT; Luciano J. Costa, University of Alabama at Birmingham, Birmingham, AL; Andrew J. Yee, Massachusetts General Hospital Cancer Center, Boston; Michael Kauffman, Sharon Shacham, Jean-Richard Saint-Martin, Carla D. Picklesimer, and Cassandra Choe-Juliak, Karyopharm Therapeutics, Newton, MA; Rafael Fonseca, Scott Van Wier, Gregory Ahmann, Ilsel Lopez, and A. Keith Stewart, Mayo Clinic of Arizona, Phoenix, AZ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.75.5207DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6905485PMC
March 2018

Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update.

J Clin Oncol 2018 03 17;36(8):812-818. Epub 2018 Jan 17.

Kenneth Anderson, Dana-Farber Cancer Institute; Noopur Raje, Massachusetts General Hospital, Boston, MA; Nofisat Ismaila, American Society of Clinical Oncology, Alexandria, VA; Patrick J. Flynn, Minnesota Oncology, Woodbury; Robert A. Kyle, Mayo Clinic, Rochester, MN; Susan Halabi, Duke University Medical Center, Durham, NC; Sundar Jagannath, Mount Sinai Medical Center, New York, NY; Mohammed S. Ogaily, Beuamont Center for Hematology and Oncology-Downriver, Brownstown, MI; Jim Omel, Education and Advocacy, Grand Island; Gary C. Yee, University of Nebraska Medical Center, Omaha, NE; and G. David Roodman, Indiana University School of Medicine, Indianapolis, IN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.6402DOI Listing
March 2018

The effect of novel therapies in high-molecular-risk multiple myeloma.

Clin Adv Hematol Oncol 2017 Nov;15(11):870-879

Icahn School of Medicine at Mount Sinai, New York, New York.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5993678PMC
November 2017

A phase II trial of TBL-12 sea cucumber extract in patients with untreated asymptomatic myeloma.

Br J Haematol 2018 01 7;180(2):296-298. Epub 2016 Oct 7.

Icahn School of Medicine at Mount Sinai, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.14314DOI Listing
January 2018

Outcomes and management of lenalidomide-associated rash in patients with multiple myeloma.

Leuk Lymphoma 2016 11 4;57(11):2510-5. Epub 2016 Mar 4.

a Hematology and Oncology, Multiple Myeloma Program , Icahn School of Medicine at Mount Sinai , New York , NY , USA ;

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.3109/10428194.2016.1
Publisher Site
http://dx.doi.org/10.3109/10428194.2016.1151507DOI Listing
November 2016

Dual Targeting of CDK4 and ARK5 Using a Novel Kinase Inhibitor ON123300 Exerts Potent Anticancer Activity against Multiple Myeloma.

Cancer Res 2016 Mar 12;76(5):1225-36. Epub 2016 Feb 12.

Department of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York. Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York.

View Article

Download full-text PDF

Source
http://cancerres.aacrjournals.org/content/early/2016/02/12/0
Web Search
http://cancerres.aacrjournals.org/cgi/doi/10.1158/0008-5472.
Publisher Site
http://dx.doi.org/10.1158/0008-5472.CAN-15-2934DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5968814PMC
March 2016

The outcomes of newly diagnosed elderly multiple myeloma patients treated at a single U.S. institution.

Cancer Med 2016 Mar 22;5(3):500-5. Epub 2016 Jan 22.

Division of Hematology Oncology, Icahn School of Medicine at Mount Sinai, Gustave Levy Place, Box 1185, New York City, New York, 10029.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.620DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4799960PMC
March 2016

Advances in targeted therapy for the treatment of patients with relapsed/refractory multiple myeloma.

Expert Rev Hematol 2016 Jan;9(1):91-105

c Department of Haematology , University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino , Torino , Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/17474086.2016.1119041DOI Listing
January 2016

Relationship Between Carfilzomib Dose and Efficacy Outcomes in Patients With Relapsed and/or Refractory Multiple Myeloma.

Clin Lymphoma Myeloma Leuk 2015 Nov 25;15(11):680-6. Epub 2015 Sep 25.

International Drug Development Institute, Louvain-la-Neuve, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2015.09.005DOI Listing
November 2015

American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma.

Biol Blood Marrow Transplant 2015 Dec 30;21(12):2039-2051. Epub 2015 Sep 30.

University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2015.09.016DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4757494PMC
December 2015

CD34-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Relapsed, High-Risk Multiple Myeloma.

Biol Blood Marrow Transplant 2016 Feb 30;22(2):258-267. Epub 2015 Aug 30.

Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Multiple Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Weill Cornell Medical College, New York, New York; Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10838791150057
Publisher Site
http://dx.doi.org/10.1016/j.bbmt.2015.08.025DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4975432PMC
February 2016

Serum Free Light Chain Assessment Early After Stem Cell Transplantation as a Prognostic Factor in Multiple Myeloma.

Clin Lymphoma Myeloma Leuk 2015 Sep 6;15(9):541-5. Epub 2015 Jun 6.

Multiple Myeloma Program, Mount Sinai School of Medicine, New York, NY. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S21522650150036
Publisher Site
http://dx.doi.org/10.1016/j.clml.2015.05.004DOI Listing
September 2015

Serum free light chain reduction correlates with response and progression-free survival following carfilzomib therapy in relapsed/refractory multiple myeloma.

Leuk Lymphoma 2015 12;56(10):2959-61. Epub 2015 May 12.

g John Theurer Cancer Center at Hackensack University Medical Center , Hackensack , NJ , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2015.1020801DOI Listing
September 2016

Asymptomatic monoclonal gammopathies.

Clin Lymphoma Myeloma Leuk 2014 Sep;14 Suppl:S78-86

Department of Hematology/Oncology, Mt Sinai Medical Center, New York, NY. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2014.05.004DOI Listing
September 2014

State of the art imaging of multiple myeloma: comparative review of FDG PET/CT imaging in various clinical settings.

Eur J Radiol 2014 Dec 28;83(12):2203-2223. Epub 2014 Sep 28.

Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY, United States. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S0720048X140045
Publisher Site
http://dx.doi.org/10.1016/j.ejrad.2014.09.012DOI Listing
December 2014

Two cases of plasma cell dyscrasias with systemic involvement of breast.

Semin Oncol 2014 Aug 26;41(4):e33-e37. Epub 2014 Jun 26.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2014.06.007DOI Listing
August 2014

Adverse drug reaction: pomalidomide-induced liver injury.

Lancet 2014 Jun;383(9935):2125-6

Division of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(14)61030-8DOI Listing
June 2014

Patients with newly diagnosed multiple myeloma and chromosome 1 amplification have poor outcomes despite the use of novel triplet regimens.

Am J Hematol 2014 Jun 30;89(6):616-20. Epub 2014 Apr 30.

Division of Hematology and Medical Oncology, Department of Medicine and the Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.23705DOI Listing
June 2014

Risk stratification in multiple myeloma, part 2: the significance of genetic risk factors in the era of currently available therapies.

Clin Adv Hematol Oncol 2013 ;11(9):578-83

Director of clinical research in the Multiple Myeloma Program and an assistant professor of medicine at the Icahn School of Medicine at Mount Sinai in New York, New York.

View Article

Download full-text PDF

Source
October 2014

Risk stratification in multiple myeloma, part 1: characterization of high-risk disease.

Clin Adv Hematol Oncol 2013 Aug;11(8):489-503

Director of Clinical Research in the Multiple Myeloma Program and an Assistant Professor of Medicine at the Icahn School of Medicine at Mount Sinai, New York, New York.

View Article

Download full-text PDF

Source
August 2013

Radiation therapy for secondary cutaneous plasmacytomas.

Case Rep Hematol 2013 24;2013:739230. Epub 2013 Oct 24.

Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2013/739230DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3821948PMC
November 2013

A case of IgD myeloma representing a missed biclonal paraproteinemia or isotype switch in a patient previously diagnosed with IgA-lambda myeloma.

Clin Chim Acta 2013 Oct 13;425:233-5. Epub 2013 Aug 13.

Mount Sinai Hospital, Dept of Pathology, Gustave L Levy Place, Box 1194, New York, NY 10128, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00098981130030
Publisher Site
http://dx.doi.org/10.1016/j.cca.2013.08.004DOI Listing
October 2013

Complete remission achieved with single agent CNTO 328, an anti-IL-6 monoclonal antibody, in relapsed and refractory myeloma.

Clin Lymphoma Myeloma Leuk 2013 Jun 10;13(3):333-7. Epub 2013 Jan 10.

Department of Medicine, Division of Hematology/Oncology, Mt Sinai School of Medicine, New York, NY 10029, USA.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S21522650120029
Publisher Site
http://dx.doi.org/10.1016/j.clml.2012.12.010DOI Listing
June 2013

A case report of chronic myelogenous leukemia in a patient with multiple myeloma and a review of the literature.

Clin Lymphoma Myeloma Leuk 2013 Apr 15;13(2):175-9. Epub 2012 Nov 15.

Division of Hematology/Oncology, Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY 10029, USA.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S21522650120017
Publisher Site
http://dx.doi.org/10.1016/j.clml.2012.09.010DOI Listing
April 2013